Literature DB >> 7149450

Histamine dose-response relationships in normal and asthmatic subjects. The importance of starting airway caliber.

K F Chung, B Morgan, S J Keyes, P D Snashall.   

Abstract

We examined the effects of pharmacologic antagonists on the bronchial response to inhaled histamine in 11 normal and 11 asthmatic subjects. We constructed cumulative log dose-response curves and determined the steepest slope and the provocative dose of histamine (PD35) needed to cause a 35% fall in specific airway conductance (SGaw). The slope was positively related to starting SGaw in both groups. Starting SGaw and slope were approximately 2-fold lower in asthmatics. After inhaling salbutamol (200 micrograms) and atropine (4 mg), there was an increase in starting SGaw and slope of the histamine response by approximately 1.5-fold in normal subjects and 2-fold in asthmatics, the relationship between starting SGaw and slope being preserved. Chlorpheniramine (4 mg) had little effect on starting SGaw and slope.l Atropine, salibutamol, and chlorpheniramine increased PD35 by approximately 4-fold in normal subjects and 6-fold in asthmatics. Afte bronchodilatation with atropine or salbutamol, mean starting SGaw, slope, and PD35 of the responses in asthmatics were similar to those of unpremedicated normal subjects. Thus, the slope of the histamine dose-response curve is largely determined by the starting airway caliber, increases in PD35 by drugs reflect in part the effects of bronchodilatation and in part their specific pharmacologic antagonist activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7149450     DOI: 10.1164/arrd.1982.126.5.849

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  12 in total

1.  Relation between the bronchial obstructive response to inhaled lipopolysaccharide and bronchial responsiveness to histamine.

Authors:  O Michel; R Ginanni; R Sergysels
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

Review 2.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

3.  Role of histamine release in hypertonic saline induced bronchoconstriction.

Authors:  S P O'Hickey; N G Belcher; P J Rees; T H Lee
Journal:  Thorax       Date:  1989-08       Impact factor: 9.139

4.  Airway calibre as a confounder in interpreting bronchial responsiveness in asthma.

Authors:  A Dirksen; F Madsen; T Engel; L Frølund; J H Heinig; H Mosbech
Journal:  Thorax       Date:  1992-09       Impact factor: 9.139

5.  Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline.

Authors:  J S Mann; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

6.  Effect of prior bronchoconstriction on the airway response to histamine in normal subjects.

Authors:  K F Chung; P D Snashall
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

7.  The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease.

Authors:  E H Bel; A H Zwinderman; M C Timmers; J H Dijkman; P J Sterk
Journal:  Thorax       Date:  1991-01       Impact factor: 9.139

8.  Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo.

Authors:  D R Baldwin; Z Sivardeen; I D Pavord; A J Knox
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

9.  The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma.

Authors:  K A Miszkiel; R Beasley; P Rafferty; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

10.  Effect of oral terfenadine on the bronchoconstrictor response to inhaled histamine and adenosine 5'-monophosphate in non-atopic asthma.

Authors:  G D Phillips; P Rafferty; R Beasley; S T Holgate
Journal:  Thorax       Date:  1987-12       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.